The dapagliflozin market is estimated at USD 267.96 million in 2026, is projected to reach USD 4,584.38 million by 2036 and is forecast to register a 32.8% CAGR between 2026 and 2036. In 2026, type 2 diabetes hold 62.0% of application sales and powder represents 61.0% within the form segment.